Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07899138

Effect of Vitamin D and Zinc Supplementation on Inflammatory Biomarkers in Pulmonary Tuberculosis Patients

Conditions: Pulmonary Tuberculosis

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 32
Sponsor: Hasanuddin University

Location: Balai Besar Kesehatan Paru Masyarakat (BBKPM) Makassar Makassar South Sulawesi

Summary

This study evaluates the effect of combined Vitamin D and Zinc supplementation on inflammatory biomarkers in pulmonary tuberculosis (TB) patients during the intensive phase of treatment. The main goal is to determine if this nutritional supplementation can help improve inflammatory levels by measuring biomarkers such as Neutrophil-to-Lymphocyte Ratio (NLR), Interleukin-6 (IL-6), and albumin.

Eligibility Criteria

Inclusion Criteria: 1. Adult patients aged 18 years or older. 2. Active pulmonary tuberculosis confirmed by positive acid-fast bacilli (AFB) sputum smear or positive molecular rapid test (GeneXpert/TCM), diagnosed by a pulmonologist. 3. Currently undergoing the intensive phase of anti-tuberculosis therapy (ATT), with the duration of ATT treatment less than 14 days since initiation at the time of recruitment. 4. Patients with vitamin D deficiency or insufficiency and zinc deficiency. 5. Patient is willing to follow all study procedures for 8 weeks and signed the written informed consent. 6. Patients who have not consumed vitamin D and/or zinc supplements within the last 30 days (wash-out period). Exclusion Criteria: 1. Patients with extra-pulmonary tuberculosis without lung involvement, or patients with suspected or confirmed MDR-TB/XDR-TB. 2. Pregnant or breastfeeding women. 3. Patients with diseases or conditions that alter vitamin D or calcium metabolism, such as hypercalcemia (total calcium \>= 10.5 mg/dL), hyperparathyroidism, or a history of recurrent calcium nephrolitiasis. 4. Severe liver failure or end-stage renal disease requiring chronic dialysis. 5. Patients taking systemic immunosuppressive drugs (e.g., prednisone equivalent \>10 mg/day for \>= 14 days), active chemotherapy, or active unstable autoimmune disease. 6. Patients with severe uncontrolled co-infections (e.g., sepsis, severe non-TB pneumonia) at the time of screening. 7. Patients with known allergy or hypersensitivity to cholecalciferol or zinc preparations used in this study. 8. Patients unable to follow the follow-up schedules or considered likely to drop out based on investigator's assessment.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07899138). StuddyBuddy aggregates publicly available trial information.